...
首页> 外文期刊>The European journal of psychiatry >Clinical trial designs of new medicinal products for treating schizophrenia: Discussion of EMA's Guideline and a Better Long Term Trial Design
【24h】

Clinical trial designs of new medicinal products for treating schizophrenia: Discussion of EMA's Guideline and a Better Long Term Trial Design

机译:用于治疗精神分裂症的新药物的临床试验设计:讨论EMA指南和更好的长期试验设计

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Objectives: Schizophrenia is a severe chronic disease. Endpoint variables lack objectivity and the diagnostic criteria have evolved with time. In order to guide the development of new drugs, European Medicines Agency (EMA) issued a guideline on the clinical investigation of medicinal products for the treatment of schizophrenia.
机译:背景与目的:精神分裂症是一种严重的慢性疾病。端点变量缺乏客观性,诊断标准随时间而发展。为了指导新药的开发,欧洲药品管理局(EMA)发布了用于治疗精神分裂症的药物临床研究指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号